<DOC>
	<DOCNO>NCT01485640</DOCNO>
	<brief_summary>This open-label continuation study design monitor safety , tolerability effectiveness lurasidone subject complete participation lurasidone extension study ( NCT00868959 NCT01566162 ) may benefit continued treatment lurasidone .</brief_summary>
	<brief_title>Lurasidone Extended Use Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>The subject legal guardian provide write informed consent . For eligible subject age 18 , verbal assent also require . The subject complete extension phase prior lurasidone clinical study . Eligible subject may enroll continuation study directly ( within 10 day ) complete extension phase prior lurasidone clinical study . Subjects complete extension study prior initiation protocol study site , may participate study 3 month completion extension phase prior lurasidone study . The subject judge Investigator suitable participation clinical study involve openlabel lurasidone treatment able comply protocol . The subject , Investigator 's judgment , may benefit continued treatment lurasidone The subject consider Investigator , imminent risk homicidal suicidal behavior . The subject resides country lurasidone approve indication . The subject currently enrol investigational study . The subject answer `` yes '' `` Suicidal Ideation '' Items 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>